- Research article
- Open Access
Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity
BMC Cancer volume 18, Article number: 466 (2018)
The addition of high-dose cytarabine to the treatment of mantle cell lymphoma (MCL) has significantly prolonged survival of patients, but relapses are common and are normally associated with increased resistance. To elucidate the mechanisms responsible for cytarabine resistance, and to create a tool for drug discovery investigations, we established a unique and molecularly reproducible cytarabine resistant model from the Z138 MCL cell line.
Effects of different substances on cytarabine-sensitive and resistant cells were evaluated by assessment of cell proliferation using [methyl-14C]-thymidine incorporation and molecular changes were investigated by protein and gene expression analyses.
Gene expression profiling revealed that major transcriptional changes occur during the initial phase of adaptation to cellular growth in cytarabine containing media, and only few key genes, including SPIB, are deregulated upon the later development of resistance. Resistance was shown to be mediated by down-regulation of the deoxycytidine kinase (dCK) protein, responsible for activation of nucleoside analogue prodrugs. This key event, emphasized by cross-resistance to other nucleoside analogues, did not only effect resistance but also levels of SPIB and NF-κB, as assessed through forced overexpression in resistant cells. Thus, for the first time we show that regulation of drug resistance through prevention of conversion of pro-drug into active drug are closely linked to increased proliferation and resistance to apoptosis in MCL. Using drug libraries, we identify several substances with growth reducing effect on cytarabine resistant cells. We further hypothesized that co-treatment with bortezomib could prevent resistance development. This was confirmed and show that the dCK levels are retained upon co-treatment, indicating a clinical use for bortezomib treatment in combination with cytarabine to avoid development of resistance. The possibility to predict cytarabine resistance in diagnostic samples was assessed, but analysis show that a majority of patients have moderate to high expression of dCK at diagnosis, corresponding well to the initial clinical response to cytarabine treatment.
We show that cytarabine resistance potentially can be avoided or at least delayed through co-treatment with bortezomib, and that down-regulation of dCK and up-regulation of SPIB and NF-κB are the main molecular events driving cytarabine resistance development.
Mantle cell lymphoma (MCL) is an aggressive B-cell lymphoma, molecularly defined by the translocation of CCND1 . The malignant cells harbor a number of molecular abbreviations such as overexpression of SOX11  and constitutive activation of the nuclear factor-κB (NF-ĸB) pathway . The NF-ĸB pathway regulates a number of genes involved in apoptosis, cell adhesion, proliferation and tissue remodeling. Especially, relapsed MCL has increased activity of the pathway which most likely has a key role in maintaining tumour cell viability and drug resistance, through overexpression of several anti-apoptotic proteins [4, 5].
Traditionally, MCL was characterized by initial sensitivity to standard chemotherapy followed by relapse, and unfavorable outcome [6, 7]. However, addition of high-dose cytarabine treatment as part of the induction therapy has resulted in great improvement in survival in subgroups of MCL patients . Cytarabine (ara-C, cytosine arabinoside) is a deoxycytidine nucleoside analogue, an S-phase specific anti-metabolite, which is used in modern MCL combinatorial treatment protocols . High-dose cytarabine is effective due to the improved retention of ara- CTP by target cells , but likewise toxic, causing mainly hematological side effects. Thus, understanding the molecular mechanism(s) responsible for resistance, identifying predictive markers for resistance and/or sensitizing agents, would be of great clinical value.
Cytarabine is a prodrug, which first needs to be transported across the plasma membrane, and secondly become activated through phosphorylation. Transportation of nucleosides and nucleoside analogues across the plasma membrane is mediated by transporter proteins belonging to the solute carrier families 28 and 29 (SLC28 and SLC29). SLC28 genes encode the three members of the concentrative nucleoside transporter (CNT) family, while the four members of equilibrative nucleoside transporter (ENT) proteins are encoded by SLC29 genes . Both ENT and CNT recognise most of the nucleoside analogues used for cancer therapy and as such they are interesting targets for further studies. For most of the nucleoside analogues commonly used for anti-cancer therapy, the first phosphorylation step is catalysed by deoxycytidine kinase (dCK). Both de novo resistance and acquired resistance to cytarabine, including cross-resistance to other nucleoside analogues, have been linked to down-regulation of dCK on gene and protein level [12,13,14].
Today, there are many treatment alternatives available for relapsed or recurrent MCL patients but only little information available on which patients that would benefit from each alternative. Thus, the aims of the present study were to (i) characterize the mechanisms of cytarabine resistance in MCL, (ii) identify drugs suitable for treatment of relapsed/recurrent MCL patients treated with Ara-C and (iii) to suggest preventive measurements based on in vitro-model data.
To do so we have established a unique MCL resistant model in which cytarabine resistance repetitively and molecularly reproducibly can be induced in a highly controlled manner. Using molecular profiling, we show that down-regulation of the dCK protein is key to development of resistance. The cellular model, representing three stages of resistance development (naïve sensitive, exposed sensitive and resistant) was further characterized using gene expression analysis and functional analysis. Key gene changes, including upregulation of the transcription factor SPIB was identified. We further show that similar to relapsed/recurrent MCLs, the resistant cells are not only defined by the lack of dCK and increased SPIB, but also high levels of NF-κB.
Functional screens using (i) chemotherapeutics or (ii) epigenetic regulators were used to identify drugs with potential cross-resistance and/or sensitivity, and to select individual epigenetic candidate drugs for sensitisation of cytarabine-resistant cells. Co-treatment with bortezomib and cytarabine prevented resistant development, but could not overcome resistance once dCK was abolished.
The importance of dCK for response to therapy was confirmed by the analysis of primary MCLs where 97% of the patients have high or intermediate dCK at diagnosis.
The MCL cell line Z138 was purchased from ATCC (Manassas, VA, USA). Both untreated and resistant cell lines were cultured in R10 medium (RPMI 1640 (HyClone Laboratories, Logan, UT, USA) supplemented with 10% fetal bovine serum (Invitrogen, Carlsbad, CA, USA) and 1% 2 mM L-glutamine (Invitrogen)).
Cytarabine (147–94-4, Pfizer, New York, NY, USA) was aliquoted and stored at 4 °C with bulk concentrations of 411 mM. SCREEN-WELL® Epigenetics library (BML-2836, Enzo LifeSciences Inc., Farmingdale, NY, USA) and Chemotherapeutic Agent Library (L1500, Selleck, Munich, Germany) were stored at − 80 °C until use. Substances used for proliferation studies including bortezomib (2204S, Cell Signaling Technologies), lenalidomide (PCID-216326 Santa Cruz Biotechnology, USA), apicidin (A8851, Sigma Aldrich), belinostat (PXD101), M-344 (M5820, Sigma Aldrich), oxamflatin (O3139, Sigma Aldrich, St. Louis, MO, USA), scriptaid (S7817, Sigma Aldrich), trichostatin A (T1952, Sigma Aldrich) and vorinostat (SAHA MK0683, Selleck) were dissolved in DMSO (Sigma Aldrich), aliquoted and stored at − 80 °C until use.
Establishment of resistant sub-clones
The first resistant sub-clone defined as Z138 Cytarabine Resistant (Z138-CytR) was established by continuous exposure of wild type Z138 Cytarabine Naïve Sensitive cells (Z138-CytNS) to increasing concentrations (0.005–0.3 μM) of cytarabine. Using this model, we could identify the approximate time to resistance development, and utilize this information for developing a novel time-controlled cytarabine resistant model, described below.
Z138-CytNS, with viability above 85%, were exposed to 0.005 μM cytarabine and kept at log phase (1–2 × 106 cells/ml). Concentrations were increased two- or ten-fold, and samples for immunoblotting were taken when viability reached above 85%. When reaching a concentration of 0.2 μM cytarabine, cells were expanded and frozen as a cell biobank, a sub-clone called Z138 Cytarabine Exposed Sensitive (Z138-CytES). This cell biobank could then be used for further cytarabine exposure experiments and the establishment of a Cytarabine Resistant 21 days (Z138-CytR21) sub-clone.
Effect of cytarabine on sensitive and resistant cell lines
Cells were seeded in a 48 well plate and incubated with 0, 0.5, 5 and 50 μM of cytarabine at 37 °C (5% CO2) for 24–96 h. Duplicates from each concentration were counted in an automatic cell counter (Countess™, Invitrogen) at each time point, and trypan blue exclusion method was used to monitor viability.
Assessment of cell proliferation by [methyl-14C]-thymidine incorporation
Cells were seeded in a Cytostar-T 96 well plate (Perkin Elmer, Waltham, MA, USA) and cultured for up to 72 h in presence of 0.5 μCi/ml [methyl-14C]-thymidine (PerkinElmer). Cell proliferation was measured at indicated time-points using a Wallac 1450 MicroBeta liquid scintillation counter (Perkin Elmer). Prior to all measurements, cells were centrifuged to allow contact to the scintillation liquid.
Re-introduction of dCK into dCK negative resistant cells
To assess the importance of dCK in relation to resistance, the protein was transiently re-introduced into resistant cells. The Amaxa protocol (Amaxa Biosystems Cologne, Germany) for nucleofection of suspension cell lines was followed, using program CM-138 and Cell Line Nucleofector Solution SF (Amaxa Biosystems). For the re-introduction experiments, 2.5 × 106 cells were mixed with 2 μg of OmicsLink™Expression Clone for dCK (EX-C0081-M46, vector information can be found in Additional file 1) in each reaction and a GFP vector was used as a positive control (both from GeneCopoeia, Germantown, MD, USA).
Gene expression analysis
Triplicate cultures of cells were harvested at different time-points and lysed in TRIzol (Invitrogen). Preparation of tRNA was performed as previously described . Gene expression was assessed using Affymetrix Human Transcriptome Array 2.0 (HTA 2.0; Affymetrix Inc., Santa Clara, CA, USA), and acquired data was pre- processed at the SCIBLU Genomics Centre (Lund University, Sweden) involving quality control and normalization, using the Expression Console software (Affymetrix Inc). Normalized and log2 transformed data was imported into Qlucore Omics Explorer 3.0 (Qlucore AB, Lund, Sweden) for statistical analysis. For confirmation of mRNA expression in different samples, TaqMan probe-based RT-PCR was performed, using TaqMan® Fast Universal PCR Master Mix (Applied Biosystem, Waltham, MA, USA) and the TaqMan assay Hs01040726_m1 (dCK, Applied Biosystem) and Hs00162150_m1 (SPIB, Applied Biosystem). 18S (Hs99999901_s1, Applied Biosystem) was used as reference gene. All data were analyzed using the 7500 software v2.0.5 (Applied Biosystem). Functional annotation of individual genes was obtained from NCBI/Gene (http://www.ncbi.nlm.nih.gov/gene), GeneCards (http://www.genecards.org/) or UniProt (http://www.uniprot.org/).
Library preparation, hybridization capture and MPS sequencing
DNA from Z138-CytNS, Z138-CytES and Z138-CytR cells were purified using RNeasy Plus Mini Kit (Qiagen, Hilden, Germany) and thereafter quantified using the Qubit system (Life Technologies, Carlsbad, CA, USA). Two μg of DNA were fragmented using the Covaris S2 Ultrasonicator (Covaris, Woburn, MA, USA) and DNA fragments from 64 target genes, including TP53 were captured using SureselectXT Custom 3–5.9 Mb library kit (Agilent Technology, Santa Clara, CA, USA). Before capture, eight samples were pooled, and the molarity of the pooled library was determined based on and DNA fragment size distribution measured on a Bioanalyzer (Agilent) and concentration measured by Qubit. Sequencing was performed on the Illumina HiSeq 2500 (Illumina, San Diego, CA, USA) with 2 × 101 bp paired end reads.
Analysis of sequencing data
Picard Extract IlluminaBarcodes and IlluminaBasecallsToSam (https://broadinstitute.github.io/picard/) was used for format conversion and demultiplexing of raw Illumina sequencing data and sequence reads were aligned to the human reference genome hs37d5ss (1000 genome with decoy sequences) using Novoalign (http://www.novocraft.com). Picard MarkDuplicates were used to identify and exclude PCR duplicates in subsequent analyses and quality scores were recalibrated and indels realigned using the Genome Analysis Tool Kit (GATK) . GATK UnifiedGenotyper with a call confidence cutoff of 10 were used to identify genetic variants and genotypes. Variants were annotated for their effect on protein coding transcripts using snpEff and Annovar using RefSeq reference transcripts. Bases of coding exons and 20 bp of adjacent introns were covered by at least 30 reads and variants affecting coding exons and 20 bp of adjacent introns were evaluated for pathogenicity.
Silencing of SPIB in the resistant cell line
Cell Line Nucleofector Solution SF was used with program CM-138 following the Amaxa protocol for suspension cell lines (Amaxa Biosystems). Cells were mixed with 1000 nM of siRNA (Ambion, Austin, TX, USA) or a scrambled sequence. GFP-producing plasmid was used as control for the transfections (Amaxa Biosystems).
Effect of bortezomib on resistance development
Based on the set up presented above, Z138-CytES cells were co-treated with 0.3 μM of cytarabine and 0.001 or 0.01 μM of bortezomib during the 21 days expected for resistance to develop. A positive control with only 0.3 μM of cytarabine was grown in parallel (as visualized in Fig. 10c). Z138-CytNS cells and Z138-CytR cells were subjected to the same treatment during the same period. Lysates for immunoblotting were sampled continuously during the treatment period and after completed treatment. After 21 days of treatment, proliferation in cytarabine containing medium was assessed by [methyl-14C]-thymidine incorporation as previously described.
Cells were harvested for western blot and lysed on ice with lysis buffer (1% NP40 (Sigma Aldrich) in PBS supplemented with 1× complete protease inhibitor (Roche Applied Sciences, Indianapolis, IN, USA)) for 30 min followed by centrifugation at 4 °C, 1300 rpm for additional 30 min. Supernatants consisting of protein lysates were collected and protein concentrations were measured using a bicinchoninic acid kit (Sigma Aldrich). For western blot, 25 μg protein was loaded on a Bis-Tris gel (Life Technologies, Carlsbad, USA). Following electrophoresis using an XCell Surelock Mini- Cell system (Life Technologies), the proteins were immediately blotted onto a PVDF membrane using program P3 on the iBlot Dry Blotting System (Life Technologies). The membranes were then blocked for 60 min with 5% milk in PBS, before incubation with primary antibodies targeting dCK (TA502698, OriGene Technologies, Rockville, MD, USA), ENT1 (ab 11,337–1-AP, Proteintech, Chicago, IL, USA), SPIB (Cell Signaling), NF- κB (D14E12, Cell Signaling), IκBα (44D4, Cell Signaling) and/or GAPDH (G8795, Sigma Aldrich). Horseradish peroxidase-conjugated rabbit anti-mouse immunoglobulin (P0260, Dako, Glostrup, Denmark) and swine anti-rabbit immunoglobulin (P0217, Dako) were used as secondary antibodies. Protein levels were visualized in a ChemiDoc™ MP Imaging System (Bio-Rad Laboratories, Hercules, CA, USA) with SuperSignal West Femto Maximum Sensitivity Substrate (ThermoFisher Scientific). Quantification of the results was performed using the Image Lab software (Version 5.2.1, Bio-Rad Laboratories).
Screening of compound libraries and validation of selected drugs
Z138-CytNS or Z138-CytR cells were seeded in a Cytostar-T 96 well plate as previously described, and treated with different concentrations of chemotherapeutic and epigenetic drugs. Non-treated cells re-suspended in R10 medium were considered as R10 controls, and DMSO (0.01%) treated cells as vehicle controls. Proliferation was measured 0, 24 and 48 h after addition of chemotherapeutic and/or epigenetic drugs. To evaluate the additive effect of epigenetic drugs to cytarabine, 50 μM cytarabine was added 6 h after pre-incubation of cells with epigenetic compounds.
Patients, cohorts and treatment protocols
Materials from patients included in the Nordic Lymphoma Group MCL2 and MCL3 trials at hospitals in Sweden, Finland, Norway and Denmark, were selected for TMA construction as previously described . The treatment protocols for MCL2 and MCL3 both include high-dose cytarabine, rituximab and ASCT as previously described .
Immunohistochemistry staining and digital scoring
Immunohistochemistry was performed as previously described . The sections were stained for dCK (TA502698; OriGene Technologies) and visually analysed using a Nikon ECLIPSE 80i microscope (Nikon Instruments Inc., Melville, NY, USA) at a magnification of 20× (Plan Flour 20× DIC M/N2, Nikon) with a numeric aperture of 0.5. Images were captured using a Nikon DS-U2/L2 USB (Nikon) camera, and NIS Elements BR 3.10 (Nikon) as acquisition software. For digital scoring, dCK stained slides were scanned at an absolute magnification of 20× (resolution of 0.493 μm per pixel) and digitally scored using HALO™ (Indica Labs, Corrales, NM, USA). Positive areas (tumour) and negative areas (stroma) were separated and quantified based on a pattern recognition algorithm in the HALO platform. Image analysis based on RGB (red, green, blue) spectra was used to detect all cells by counterstaining with hematoxylin (blue). All analysis settings including thresholds set for weak, intermediate and strong nuclei staining were maintained throughout the whole study (Additional file 2: Table S1).
Establishment of reproducible cytarabine resistant sub-clones from the MCL cell line Z138
The Z138 cell line is originally derived from a MCL patient with blastoid transformation, and cells carry the 11;14 translocation and overexpress cyclin D1 . The untreated Z138 cell line, hereafter referred to as Z138-CytNS (Z138 Cytarabine Naïve Sensitive) is highly sensitive toward cytarabine and does not survive concentrations at, or above 0.5 μM (Fig. 1a).
Z138-CytNS cells were exposed to increasing concentrations (0.005–0.3 μM) of cytarabine to investigate and define the number of days required to induce resistance upon continuous exposure. After approximately 60 days, a highly cytarabine resistant sub-clone, Z138-CytR, was established growing at an unaffected rate in up to 50 μM cytarabine (Fig. 1b).
With this information at hand, new cell cultures were initiated with the aim to establish a reproducible model where resistance could be induced in a time-controlled manner from a permanent source of viable frozen pre-exposed cells. Thus, Z138-CytNS cells were exposed to increasing concentrations of cytarabine and when reaching high viability (> 85%) at 0.2 μM, cells were expanded, without addition of cytarabine, and frozen to establish a large and renewable pool of cells with defined time to resistance development. From this pool of frozen cells (referred to as Z138-CytES), later experiments showed that complete resistance (defined as unaffected proliferation at the 50 μM cytarabine concentration) reproducibly can be achieved in ~ 21 days upon exposure to 0.3 μM cytarabine. To be able to investigate the difference in molecular response to cytarabine exposure and the molecular signature related to resistance development, control cells were cultivated in parallel without cytarabine during the last 21 days. A schematic representation of the experimental set-up and designation of samples at the different time-points of cytarabine exposure is shown in Fig. 1c. Comparison of cytarabine resistance in control (Z138-CytES21) and long-term cytarabine exposed cells (Z138-CytR21) showed that although control cells can be kept viable in 0.2 μM cytarabine (data not shown), they do not proliferate (Fig. 1d). Further comparison of replicates (n = 3) of cytarabine exposed cells and control cells at different time-points show a reproducible resistance of cells up to 50 μM, but loss of proliferation at 500 μM cytarabine (Fig. 1e).
As p53 status is a prognostic factor for patients treated with cytarabine-containing regimens , the TP53 status was investigated in both untreated and cytarabine-treated cells. All samples were shown to contain only TP53 WT alleles (data not shown). Proliferation was also investigated and shown to be similar in all three stages of resistance development (Additional file 2: Figure S1).
Decreased expression of dCK and ENT during adaptation and development of resistance
It is previously known that cytarabine is dependent on the transport protein ENT1 to cross the cell membrane , and the dCK enzyme for phosphorylation into the active ara-CTP . To evaluate the hypothesis that one of these important components is involved in the resistance development in MCL, we investigated the expression of the two proteins at various time-points of cytarabine exposure. Results show that ENT1 levels start to drop after approximately 7 days of exposure to 0.3 μM cytarabine, Z138-CytES7 (Fig. 2), but no further decrease is seen as the resistance fully develop (Z138-CytES14 compared to Z138-CytR21). Analysis of dCK show that only minor down-regulation is seen during the continuous exposure to cytarabine, but an abrupt abolishment of dCK co-occurs with resistance development (Z138-CytES14 compared to Z138-CytR21, Fig. 2). This is consistent in all three parallel experiments (Additional file 2: Figure S2).
Recovery studies, where Z138-CytR cells completely lacking dCK expression were cultured in cytarabine-free medium for up to 8 weeks, did not show any indication of regained dCK protein expression or activity (data not shown). Although the selection pressure was merely sustained and not increased over the 21 days separating the Z138-CytES0 cells from Z138-CytR21 cells (Fig. 1d), the dCK expression was not completely lost until 21 days of exposure to 0.3 μM cytarabine. The expression of dCK was validated through TaqMan probe-based RT-PCR, where a significant down-regulation of dCK could be confirmed in both Z138-CytES and Z138-CytR21 compared to Z138-CytNS. No significant change in dCK mRNA levels was seen comparing cells grown with (CytR) or without cytarabine (CytES21) for 21 days beyond ES cells (Fig. 3). Based on this data, we draw the conclusion that the strongest association between cytarabine resistance and dCK is on protein level.
The results show that complete loss of dCK is crucial for cytarabine resistance and that cells adapt gradually, with initial increased viability and later restored/increased proliferation when exposed to a fixed concentration of cytarabine.
Re-introduction of dCK in CytR cells restore sensitivity to high concentrations of cytarabine
To validate the direct effect of dCK on resistance, a transient re-introduction of dCK in resistant cells was performed. DCK cDNA (see Additional file 1) and a control vector containing GFP were introduced via nucleofection. Cell viability was 80–85% 24-48 h after nucleofection of both control and dCK plasmid (data not shown).
Protein expression was restored to levels correlating to Z138-CytNS cells (Fig. 4a). Z138-CytR cells where dCK expression had been transiently re-introduced (dCK+) were more sensitive to high concentrations of cytarabine, but the effect was less prominent for concentrations below 50 μM (Fig. 4b). This may be due to that the transfection efficiency measured after 24 h was around 65–80% (data not shown) and thus resistant clones, lacking dCK, remained.
Gene expression analyses reveals major changes in transcription during adaptation, and the key protein SPIB related to development of resistance
To molecularly investigate resistance development, gene expression analysis was performed with resistant (Z138-CytR21) and control cells, from three different time-points (Z138-CytNS, Z138-CytES, Z138-CytES21 (CTR)). The microarray data was analysed in order to identify unique genes and/or gene signatures associated to (i) adaptation, or (ii) resistance. Upon two group comparisons of cytarabine naïve sensitive (Z138-CytNS) and cytarabine exposed sensitive (Z138-CytES) cells, 68 genes (Fig. 5a, Additional file 2: Table S3) were found as significantly (q < 0.05) deregulated and associated to the adaptation with high viability in presence of 0.2 μM cytarabine. Further analysis revealed that only minor transcriptional changes co-occur with the later phase of resistance development (Z138-CytES compared to Z138-CytR21). In total, 3 genes; FABP5, SPIB and TCEA3 (Fig. 5b, Additional file 2: Table S3) were found to be significantly (q < 0.05) deregulated. The upregulation of genes between Z138-CytES and Z138-CytR could be confirmed with TaqMan probe based RT-PCR (Fig. 5c), but both here and on protein level, SPIB showed the highest increase of expression in Z138-CytR compared to Z138-CytNS cells (Fig. 5d). In contrast to the mRNA, SPIB protein show increased level already in the Z138-CytES cells.
Cytarabine resistant cells show increased levels of NF-κB and IκBα
MCL is known to be dependent on constitutive activation of NF-κB, and as SPIB has been reported to regulate this pathway in other lymphomas  we investigated the activity of the pathway in the different subclones. Increased activity in the resistant cells was confirmed through western blot which showed major increase in both total NF-κB and IκBα in Z138-CytR cells (Fig. 6a). Of note, re-introduction of dCK into resistant cells using transient overexpression, decreased the protein levels of SPIB, NF-κB and IKBα back to the original levels of untreated cells (Fig. 6b-c), indicating that dCK not only affect conversion of the pro-drug to active substance but also affect molecular pathways of importance for proliferation, differentiation and apoptosis.
Knock-down of SPIB partly restores the sensitivity towards high doses of cytarabine in resistant cells
To further understand the identified relation between SPIB upregulation and cytarabine resistance, SPIB was partly knocked-down using siRNA. SPIB mRNA decreased about 50% compared to the control 48 h after transfection (Fig. 7a). Western blot analysis revealed that protein levels were consistent with the decrease on mRNA level, with almost 40% less expression in knocked-down cells compared to control (Fig. 7b). This partial silencing decreased the proliferation of resistant cells with about 25% compared to the control cells in 50 μM cytarabine (Fig. 7c), but dCK protein levels were not restored. This indicates that SPIB does not directly regulate dCK.
Z138-CytR cells are cross-resistant to other nucleoside analogues but sensitive to several clinically relevant drugs
To investigate the potential cross-resistance of Z138-CytR cells to other cytostatic compounds, a library of 40 chemotherapeutic agents was used to assess proliferation upon exposure to the substances at four different concentrations. The relative sensitivity of cytarabine naïve sensitive (Z138-CytNS) and cytarabine resistant cells (Z138-CytR) was compared (Additio0nal file 1: Figure S3A-B). Results show that Z138-CytR, were cross-resistant to all nucleoside analogues evaluated (cladribine, fludarabine and gemcitabine), defined as < 50% reduction in proliferation, compared to the DMSO control, at any of the concentrations used (Additional file 2: Figure S3B, filled dark bars). The resistance to cladribine, fludarabine and gemcitabine was confirmed in separate experiments with a wider concentration range (Fig. 8). Wild type cells were sensitive to gemcitabine and cladribine, and thus cross-resistance is detected already at low concentrations (0.01 and 0.1 μM respectively) while reduction of proliferation after exposure to fludarabine was seen at or above 1 μM.
Interestingly, comparing the response of cytarabine naïve sensitive and cytarabine resistant cells to treatment with 1 and/or 10 μM chemotherapeutic library, eleven substances were identified to have an anti-proliferative effect (defined as > 50% reduction in proliferation compared to DMSO control) on both Z138-CytNS and Z138-CytR cells (Additional file 2: Figure S3, empty bars). These include topotecan HCl, teniposide, oxaliplatin, vincristine, paclitaxel, mitoxantrone hydrochloride, etoposide, docetaxel, cerubidine and doxorubicin and are thus of interest for treatment of patients who relapse on cytarabine-containing regiments.
Histone deacetylase inhibitors have a stand-alone effect in cytarabine resistant cells and show a weak tendency to restore cytarabine sensitivity
To evaluate the stand-alone effect of various epigenetic drugs, a library of 43 epigenetic substances was used to assess sensitivity in cytarabine resistant cells. Eleven of the tested reagents from the epigenetic library had a stand-alone effect (defined as > 50% reduction in proliferation compared to DMSO control) on Z138-CytR cells at 10 μM (Additional file 2: Figure S4A right, filled dark bars). Of note, a majority of the effective compounds were histone deacetylase (HDAC) inhibitors.
For further validation, six compounds (apicidin, M-344, oxamflatin, scriptaid, trichostatin A and vorinostat) effective already at 1 μM (Additional file 2: Figure S4A left, filled dark bars) were selected (BML-281 and NSC-3852 were not commercially available in larger quantities). An additional HDAC inhibitor, not included in the library (belinostat) and a negative DMSO control were also included in the further evaluation. All substances, except for the negative control exhibited an inhibitory effect on Z138-CytR cell proliferation at concentrations above 1 μM (Additional file 2: Figure S4-B).
Similar effects were observed for the cytarabine naïve sensitive (Z138-CytNS) cells (Additional file 2: Figure S5). Based on these observations, additional experiments were performed in order to investigate the potential sensitizing effect on cytarabine resistant cells. Z138-CytR cells were exposed to a wide range of concentrations for 6 h prior to addition of cytarabine. A number of the HDAC inhibitors showed tendencies to induce cytarabine sensitivity in Z138-CytR cells at their lowest concentrations (0.1–0.5 μM), but for two of them, the difference between growth with or without cytarabine was significant also for the DMSO control, indicating that these results may be false positive (Fig. 9). Taken the effect of cytarabine alone into account, belatonin, M-344, trichostatin A and vorinostat stand out as possible sensitizers. A longer exposure time than 6 h was not technically feasible, which may have limited the impact of the epigenetic drugs.
Previous attempts to re-sensitize cells with resistance to nucleoside analogues include treatment with melatonin, an indolamine that overcome resistance to clofarabine by increasing expression of dCK . However, in our system co-culture with melatonin or hydralazine could not re-sensitize cells to cytarabine after dCK down-regulation (data not shown).
Resistant cells show slightly increased sensitivity towards lenalidomide and ibrutinib
In our search for drugs effective against cytarabine-resistant cells, both a targeted and library approach was used. It is well known that both ibrutinib and lenalidomide targets the NF-κB pathway, and thus the sensitivity towards these drugs was assessed. Z138-CytR and Z138-CytES cells showed significantly increased sensitivity towards 50 μM ibrutinib compared to Z138-NS, although at such high concentrations, proliferation is severely impaired for all subclones (Additional file 2: Figure S6A). The sensitivity towards lenalidomide was also significantly increased for both Z138-CytR and Z138-CytES cells compared to Z138-NS (Additional file 2: Figure S6B), although at a low magnitude.
Bortezomib treatment prevents resistance development
Bortezomib acts on the NF-κB pathway by preventing the degradation of IκBα. We could confirm that Z138-CytR cells were more sensitive to bortezomib concentrations above 0.005 μM compared to Z138-NS (Fig. 10a-b) while lower concentrations did not affect proliferation (Additional file 2: Figure S1B). We hypothesized that continued exposure to the drug would alter the possibility of the cells to acquire resistance to cytarabine, either through the decreased degradation of IκBα or through changes in proteins regulating dCK on the protein level. To assess this, the cell model was used to co-treat cells with cytarabine and a low concentration of bortezomib during the 21 days expected for resistance to occur (Fig. 10c). The concentration was selected to avoid effect on proliferation. Co-treatment with 0.001 μM bortezomib and 0.3 μM cytarabine prevented the expected down-regulation of dCK (Fig. 10d) and as a result the Z138-CytES cells remained sensitive towards cytarabine (Fig. 10e). Z138-CytR cells remained dCK negative after long-term exposure (3 weeks) to bortezomib, and thus retained their resistance to cytarabine. To assess whether resistance was prevented or merely delayed by prolongated proliferation, relative cell number was monitored throughout the co-treatment study, and no difference in growth rate could be detected for Z138-CytR cells co-treated with bortezomib compared to those grown in cytarabine alone (Additional file 2: Figure S1B).
Moderate to high expression of dCK is common in MCL diagnostic samples and corresponds well to initial successful response to cytarabine-containing treatment
Protein levels of dCK were stained for and automatically scored in 124 diagnostic samples from patients from the MCL2/3 cohort. Information on intensity and frequency of positive cells could be combined to define dCK strong (> 55% positive cells, n = 78), dCK intermediate (< 55% positive cells, n = 42) and dCK negative samples (> 90% negative cells, n = 4) (Fig. 11, and Additional file 2: Table S2). Thus, 120 of 124 patients (97%) had extensive dCK expression in the diagnostic sample, corresponding to the overall initial high response to treatment with cytarabine-containing regiments with 95% of the patients in the MCL2/3 cohort are progression free 6 months after inclusion to trial. As the number of dCK negative/weak patients where low, it was not statistical feasible to evaluate differences in survival.
Resistance to cytarabine is a significant clinical problem, as this agent is part of the backbone of treatment in a wide range of malignancies, including MCL. Thus, ways of predicting and possibly prevent cytarabine resistance are needed. The aim of the present study was to further explore the mechanisms of cytarabine resistance in MCL, to identify drugs suitable for treatment of patients with relapsed/recurrent disease and to identify preventive measures. To address these important clinical questions, we have established a unique MCL resistant model, based on the cell line Z138, in which cytarabine resistance repetitively in a timely and molecularly reproducibly manner can be induced. This cellular model allows for the first time resistance to be studied over time, and thus constitute an important research tool, despite the obvious drawback of being based on a single cell line It is known that dCK which is a key enzyme in converting cytarabine to active drug is dependent on functional p53 . To ensure that the developed resistance was not caused by introduction of TP53 mutations due to cellular stress and selection pressure, the resistant cells were sequenced and found to contain only TP53 WT alleles.
Transportation and activation of cytarabine is mediated by several classes of transporters and activating enzymes, such as ENT  and dCK , as described in more detail elsewhere . Using molecular profiling, we show that in our model, down-regulation of ENT1 is associated with adaptation to cytarabine exposure, but no further decrease is seen upon final development of resistance. Thus, in our model, ENT1 is not the limiting factor for resistance development, but rather a stand-by effect related to exposure to cytarabine. Also, previous studies using MCL cell lines show that there is a correlation between the expression of ENT1 and sensitivity to nucleoside analogues such as gemcitabine . In childhood AML patients, sensitivity towards nucleoside analogues could be linked to ENT1 mRNA levels, with decreased levels of ENT1 in cytarabine resistant compared to sensitive patients . However, it is not clear from these studies whether the down-regulation of ENT1 is a bystander effect, as our results indicate, or the limiting factor for drug sensitivity.
In the current study, we show that the final step of resistance development is associated with a complete down-regulation of the dCK protein. To investigate if the cellular levels of dCK protein is regulated at the transcriptional level, we performed gene expression analysis followed by RT-PCR validation. We show that dCK mRNA is down-regulated upon exposure and adaptation to cytarabine, but with minor additional down-regulation upon resistance development, indicating that post-translational modification may be involved in the final steps of resistance development. The relation between the dCK mRNA level and enzymatic activity has been explored previously. For example, using gemcitabine treatment in tumours of different origin such as pancreas and lung, it was shown that resistance only is predicted by dCK activity and protein level, and not by dCK mRNA level , in agreement with our data. DCK enzymatic activity is controlled by phosphorylation at Ser-74 , and dephosphorylation decreases enzyme activity . A more active mutant of dCK, with a 10,000-fold increased sensitivity to nucleoside analogues has been created and could be of interest for suicide gene approaches [10, 31]. Of note, in our hands forced overexpression of dCK had a direct effect on sensitivity to cytarabine in our model, indicating that protein levels govern resistance but that post-translational modification adjust the level of resistance.
To further molecularly characterize the two distinct phases of (i) cytarabine adaptation and (ii) resistance development, global gene expression analysis was performed. Analysis reveals that major changes (68 genes) in gene expression could be associated with the initial adaptation to growth in cytarabine containing media. In contrast, only a few genes (FABP5P7, FABP5P1, FABP5, SPIB and TCEA3) showed expression changes upon final resistance development. Among those genes, SPIB showed major changes on the protein level. It is known from previous reports that SPIB is frequently overexpressed in diffuse large B cell lymphomas (DLBCL), and is a poor prognostic factor . Of note, SPIB and IRF4 have been shown to amplify NF-ĸB signalling by transactivating CARD11 . SPIB has not previously been described in relation to MCL and the connection to increased NF-ĸB activity in our model is of major interest. NF-ĸB is highly active in MCL and is considered to be a key feature for the aggressiveness of MCL . Constitutively active NF-κB in MCL may be caused by different factors such as, chronic activation of the B cell receptor (BCR) or mutations in the Toll like receptor (TLR) signalling pathway. When the activation is a result of somatic mutations on inhibitors of the alternative pathway, the activation is unaffected by BCR inhibitors . To pursue if the increased aggressiveness of the resistant cells could be related to enhanced NF-ĸB activity, related proteins were investigated. Analysis showed that the resistant cells have elevated levels of both NF-ĸB total protein as well as IκBα, indicating increased engagement of the pathway in dCKnegative/SPIBhigh cells exhibiting resistance to cytarabine. Of major interest, forced overexpression of dCK led to decreased SPIB and NF-ĸB levels showing for the first time that dCK not only have an impact on the conversion of pro-drugs into active drugs, but also contribute to resistance through direct transcriptional control of pathways involved in proliferation and apoptosis. DCK as a key-driver was further pin-pointed by the fact that knock-down of SPIB did not affect dCK or NF-ĸB levels, although cytarabine resistance was slightly affected. Thus, SPIB does not regulate dCK levels but is likely associated with increased resistance through other means.
As NF-ĸB seem to play a major role in resistance we assessed if drugs known to be able to affect NF-ĸB activity, such as the immune-modulating drug lenalidomide  and the Bruton tyrosine kinase (BTK) inhibitor ibrutinib , had increased activity in the resistant cells. However, it was only at high concentrations of lenalidomide and Ibrutinib that the resistant cells had a significant increased sensitivity to cytarabine treatment.
In order to identify clinically relevant drugs effective in cytarabine resistant cells, a library of chemotherapeutic compounds was used. Eleven drugs, some predominantly used in treatment of solid cancers, and to less extent in treatment of leukemias and lymphomas, showed strong anti-proliferative effect on cytarabine resistant cells. Interestingly, four of the eleven drugs have already been considered in treatment of MCL, either as part of standard therapy (doxorubicin and vincristine) or as part of clinical trials including refractory MCL (mitoxantrone  and etoposide ). Also previous studies on cytarabine resistant leukaemia cells show that such cells are sensitive to vincristine and mitoxantrone , supporting the clinical usefulness of these drugs for treatment of cytarabine-resistant disease. Novel drugs that may have a clinical role for treatment of cytarabine-resistant disease included topotecan HCl, teniposide, oxaliplatin, paclitaxel, docetaxel and cerubidine.
As expected, cytarabine resistant cells showed cross-resistance to other nucleoside analogues, including gemcitabine, cladribine and fludarabine, emphasizing the specificity of our model, development of nucleoside analogue-resistant cells and not a general increased drug resistance [12, 14].
It has been proposed that the down-regulation of dCK is mediated by epigenetic mechanisms [39, 40] and in order to evaluate if epigenetic drugs have a potent (i) stand-alone effect or potentially, (ii) a sensitizing effect, a library with epigenetic compounds was evaluated. Of interest, most of the compounds that showed inhibitory effect on cytarabine resistant cells were HDAC inhibitors. The potential of these compounds to re-sensitize resistant cells to cytarabine was assessed through pre-incubation prior to cytarabine exposure. Some of the compounds showed a minor tendency to increase cytarabine sensitivity after pre-treatment with low concentrations of HDAC inhibitors. Potentially, a longer pre-treatment would have generated a larger impact on cytarabine resistance. HDAC inhibitors generally have low toxicity and although further pre-clinical studies are needed, inclusion of such inhibitors in combination with cytarabine should be considered.
Our present data pinpoints the importance of dCK for resistance development, and thus ways of preventing and restoring dCK activity would have a major clinical impact for treatment of MCL patients. Several previous studies have used different approaches to increase dCK activity and thus revert cytarabine resistance. Among others, it has been shown that dCK was silenced through promoter DNA methylation, and that demethylation can restore dCK levels . However, in our hands neither decitabine nor hydralazine resulted in restored sensitivity.
From our data, it is clear that dCK activity is governed by mechanisms at the protein level and we hypothesized that co-treatment with bortezomib, a proteasome inhibitor, could prevent down-regulation of dCK and development of resistance. Bortezomib, is a reversible proteasome inhibitor, primarily used in MCL as part of combinatorial therapy and approved for treatment of relapsed MCL . Inhibition of the NF-κB pathway, leading to apoptosis, has been reported as a major mechanism of action for bortezomib  and that correlates well with our model, showing increased sensitivity to bortezomib (at concentrations above 0.005 μM) in resistant cells compared to sensitive. Interestingly, the effects of bortezomib were much more prominent than for both lenalidomide and ibrutinib. The difference may partly be explained by the fact that the targets of bortezomib affects proteins more directly involved in NF-κB activation and regulation. However, being a proteasome inhibitor the action of bortezomib is not specific for the NF-κB pathway and several other cellular targets and pathways may be affected. Co-treatment with bortezomib prevented the development of cytarabine resistance and constitute a very attractive complement to cytarabine treatment in clinical protocols. Proliferation was assessed and no difference in growth rate was observed between cells co-cultured with both bortezomib (at 0.001 μM) and cytarabine compared to cells treated with cytarabine alone, ruling out the possibility that the resistance was prevented due to decreased proliferation. To our knowledge, this is the first time that it has been shown that cytarabine resistance can be prevented, which is of major clinical importance. As bortezomib is an already approved drug, implementation into the clinic should be rapid. It should be noted however, that the concentrations used in our study is in the low-end of the bortezomib serum levels measured in patients treated within current dosing regiments . Previous studies have demonstrated a synergy effect of bortezomib and cytarabine both in vitro and in individual case reports  and also as part of a small combinatorial therapy trial . A clinical trial is currently ongoing, where bortezomib was combined with cytarabine for treatment of relapse patients, and results may shed light on the efficacy of this co-treatment . Diagnostic/pre-treatment levels of dCK have in a previous study been shown to predict in vivo gemcitabine sensitivity in human tumour xenografts (pancreas, colon, ovarian cancer) . Thus, using a cohort of patients treated with the combinatorial Nordic MCL2/3 protocol, where 95% of the patients are progression free ≥6 months after therapy including high-dose cytarabine, we investigated the diagnostic levels of dCK. The dCK levels were automatically scored to identify both frequency of positive tumour cells, but also intensity of nuclear dCK levels. Ninety seven percent of the patients showed high or intermediate expression of dCK, corresponding to the high clinical response to the cytarabine-containing combinatorial protocol. Thus, the number of dCK negative/weak patients were too few to evaluate impact on survival. Today, material from relapsed MCLs is not available but constitute an important work material to study to validate our finding of down-regulation of dCK and development of cytarabine resistance.
With the aim to understand the molecular mechanisms of cytarabine resistance in MCL and identify substances that can be used to treat refractory and relapsed disease, we have established a cytarabine resistant in vitro model. This model has been used to show that cytarabine resistance occurs as a result of complete dCK down-regulation and that resistant cells show increased SPIB and NF-κB. We show for the first time that dCK not only is associated with phosphorylation of pro-drugs, but also directly affect SPIB and NF-κB levels in resistant cells, and thus have impact on pathways crucial for proliferation and resistance to apoptosis. The use of chemotherapeutic and epigenetic compound libraries has pin-pointed clinically relevant drugs that can be used to treat resistant disease. Of note, co-treatment with bortezomib prevented down-regulation of dCK and development of resistance and may have an immediate clinical impact on the treatment of MCL patients. The results that were based on a single cell line have generated hypothesis regarding how cytarabine-resistance may be avoided and targeted in the clinic, and should be further validation in clinical material such as collection of relapsed samples and samples from clinical studies with combined use of bortezomib and cytarabine.
Concentrative nucleoside transporter
Diffuse large B cell lymphoma
Equilibrative nucleoside transporter
Inhibitor of nuclear factor kappa B alpha
Mantle cell lymphoma
Nuclear factor kappa B
Z138-Cytarbine Exposed Sensitive
Z138-Cytarbine Naïve Sensitive
Z138-Cytarbine Resistant 21 days
Levine PH, Hoover R. The emerging epidemic of non-Hodgkin's lymphoma: current knowledge regarding etiological factors. Cancer Epidemiol Biomarkers Prev. 1992;1:515–7.
Ek S, Dictor M, Jerkeman M, Jirström K, Borrebaeck CAK. Nuclear expression of the non–B-cell lineage Sox11 transcription factor identifies mantle cell lymphoma. Blood. 2008;111:800–5.
Pham LV, Tamayo AT, Yoshimura LC, Lo P, Ford RJ. Inhibition of constitutive NF-κB activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol. 2003;171:88–95.
Chaturvedi NK, Rajule RN, Shukla A, Radhakrishnan P, Todd GL, Natarajan A, Vose JM, Joshi SS. Novel treatment for mantle cell lymphoma including therapy-resistant tumor by NF-κB and mTOR dual-targeting approach. Mol Cancer Ther. 2013; https://doi.org/10.1158/1535-7163.MCT-13-0239.
Wu C, de Miranda NFCC, Chen L, Wasik AM, Mansouri L, Jurczak W, Galazka K, Dlugosz-Danecka M, Machaczka M, Zhang H, et al. Genetic heterogeneity in primary and relapsed mantle cell lymphomas: impact of recurrent CARD11 mutations. Oncotarget. 2016;7:38180–90.
Dreyling M, Kluin-Nelemans HC, Bea S, Klapper W, Vogt N, Delfau-Larue MH, Hutter G, Cheah C, Chiappella A, Cortelazzo S, et al. Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 11th annual conference of the European mantle cell lymphoma network. Leuk Lymphoma. 2013;54:699–707.
Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Trneny M, Geisler CH, Stilgenbauer S, Thieblemont C, Vehling-Kaiser U, Doorduijn JK, et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med. 2012;367:520–31.
Geisler CH, Kolstad A, Laurell A, Jerkeman M, Raty R, Andersen NS, Pedersen LB, Eriksson M, Nordstrom M, Kimby E, et al. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. Br J Haematol. 2012;158:355–62.
Geisler CH, Kolstad A, Laurell A, Andersen NS, Pedersen LB, Jerkeman M, Eriksson M, Nordström M, Kimby E, Boesen AM, et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo–purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic lymphoma group. Blood. 2008;112:2687–93.
Preisler HD, Rustum Y, Priore RL. Relationship between leukemic cell retention of cytosine arabinoside triphosphate and the duration of remission in patients with acute non-lymphocytic leukemia. Eur J Cancer Clin Oncol. 1985;21:23–30.
Marcé S, Molina-Arcas M, Villamor N, Casado F, Campo E, Pastor-Anglada M, Colomer D. Expression of human equilibrative nucleoside transporter 1 (hENT1) and its correlation with gemcitabine uptake and cytotoxicity in mantle cell lymphoma. Hematol J. 2006;91:895–902.
Klanova M, Lorkova L, Vit O, Maswabi B, Molinsky J, Pospisilova J, Vockova P, Mavis C, Lateckova L, Kulvait V, et al. Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents. Mol Cancer. 2014;13:159.
Yamauchi T, Uzui K, Nishi R, Shigemi H, Ueda T. Reduced drug incorporation into DNA and antiapoptosis as the crucial mechanisms of resistance in a novel nelarabine-resistant cell line. BMC Cancer. 2014;14:547.
Dumontet C, Fabianowska-Majewska K, Mantincic D, Callet Bauchu E, Tigaud I, Gandhi V, Lepoivre M, Peters GJ, Rolland MO, Wyczechowska D, et al. Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562. Br J Haematol. 1999;106:78–85.
Kuci V, Nordstrom L, Conrotto P, Ek S. SOX11 and HIG-2 are cross-regulated and affect growth in mantle cell lymphoma. Leuk Lymphoma. 2016;57(8):1883–92. https://doi.org/10.3109/10428194.2015.1121257.
McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly M, et al. The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20:1297–303.
Nordström L, Sernbo S, Eden P, Grønbæk K, Kolstad A, Räty R, Karjalainen M-L, Geisler C, Ralfkiær E, Sundström C, et al. SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma – a Nordic lymphoma group study. Br J Haematol. 2014;166:98–108.
Medeiros LJ, Estrov Z, Rassidakis GZ. Z-138 cell line was derived from a patient with blastoid variant mantle cell lymphoma. Leuk Res. 2006;30:497–501.
Eskelund CW, Dahl C, Hansen JW, Westman M, Kolstad A, Pedersen LB, Montano C, Husby S, Freiburghaus C, Ek S, et al. TP53 mutations identify younger mantle cell lymphoma patients that do not benefit from intensive chemoimmunotherapy: data from the Nordic MCL2 and MCL3 trial cohorts. Blood. 2017;130:1903–10.
Mackey JR, Baldwin SA, Young JD, Cass CE. Nucleoside transport and its significance for anticancer drug resistance. Drug Resist Updat. 1998;1:310–24.
Grant S. Ara-C. cellular and molecular pharmacology. In: FVW G, George K, editors. Advances in Cancer research, Academic Press; 1997;72:197–233. https://doi.org/10.1016/S0065-230X(08)60703-4.
Takagi Y, Shimada K, Shimada S, Sakamoto A, Naoe T, Nakamura S, Hayakawa F, Tomita A, Kiyoi H. SPIB is a novel prognostic factor in diffuse large B-cell lymphoma that mediates apoptosis via the PI3K-AKT pathway. Cancer Sci. 2016;107:1270–80.
Yamanishi M, Narazaki H, Asano T. Melatonin overcomes resistance to clofarabine in two leukemic cell lines by increased expression of deoxycytidine kinase. Exp Hematol. 2015;43:207–14.
Staub M, Eriksson S. The role of deoxycytidine kinase in DNA synthesis and nucleoside analog activation. In: Deoxynucleoside analogs in cancer therapy: Springer; 2006. p. 29–52. https://doi.org/10.1007/978-1-59745-148-2_2.
Jordheim LP, Durantel D, Zoulim F, Dumontet C. Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. Nat Rev Drug Discov. 2013;12:447–64.
Marce S, Molina-Arcas M, Villamor N, Casado F, Campo E, Pastor-Anglada M, Colomer D. Expression of human equilibrative nucleoside transporter 1 (hENT1) and its correlation with gemcitabine uptake and cytotoxicity in mantle cell lymphoma. Haematol. 2006;91:895–902.
Hubeek I, Stam R, Peters G, Broekhuizen R, Meijerink J, van Wering E, Gibson B, Creutzig U, Zwaan C, Cloos J, et al. The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia. Br J Cancer. 2005;93:1388–94.
Kroep JR, Loves WJ, van der Wilt CL, Alvarez E, Talianidis I, Boven E, Braakhuis BJ, van Groeningen CJ, Pinedo HM, Peters GJ. Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. Mol Cancer Ther. 2002;1:371–6.
Smal C, Vertommen D, Bertrand L, Ntamashimikiro S, Rider MH, Van Den Neste E, Bontemps F. Identification of in vivo phosphorylation sites on human deoxycytidine kinase. Role of Ser-74 in the control of enzyme activity. J Biol Chem. 2006;281:4887–93.
Amsailale R, Beyaert M, Smal C, Janssens V, Van Den Neste E, Bontemps F. Protein phosphatase 2A regulates deoxycytidine kinase activity via Ser-74 dephosphorylation. FEBS Lett. 2014;588:727–32.
Coulibaly ST, Rossolillo P, Winter F, Kretzschmar FK, Braye M, Martin DP, Lener D, Negroni M. Potent sensitisation of Cancer cells to anticancer drugs by a quadruple mutant of the human deoxycytidine kinase. PLoS One. 2015;10:e0140741.
Yang Y, Shaffer AL 3rd, Emre NC, Ceribelli M, Zhang M, Wright G, Xiao W, Powell J, Platig J, Kohlhammer H, et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell. 2012;21:723–37.
Fu L, Lin-Lee YC, Pham LV, Tamayo A, Yoshimura L, Ford RJ. Constitutive NF-kappaB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B-cell lymphomas. Blood. 2006;107:4540–8.
Witzig TE, Vose JM, Zinzani PL, Reeder CB, Buckstein R, Polikoff JA, Bouabdallah R, Haioun C, Tilly H, Guo P, et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma. Ann Oncol. 2011;22:1622–7.
Rahal R, Frick M, Romero R, Korn JM, Kridel R, Chun Chan F, Meissner B, Bhang H-E, Ruddy D, Kauffmann A, et al. Pharmacological and genomic profiling identifies NF-[kappa] B-targeted treatment strategies for mantle cell lymphoma. Nat Med. 2014;20:87–92.
Forstpointner R, Unterhalt M, Dreyling M, Bock HP, Repp R, Wandt H, Pott C, Seymour JF, Metzner B, Hanel A, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German low grade lymphoma study group (GLSG). Blood. 2006;108:4003–8.
Coleman M, Martin P, Ruan J, Furman R, Niesvizky R, Elstrom R, George P, Leonard J, Kaufmann T. Low-dose metronomic, multidrug therapy with the PEP-C oral combination chemotherapy regimen for mantle cell lymphoma. Leuk Lymphoma. 2008;49:447–50.
Negoro E, Yamauchi T, Urasaki Y, Nishi R, Hori H, Ueda T. Characterization of cytarabine-resistant leukemic cell lines established from five different blood cell lineages using gene expression and proteomic analyses. Int J Oncol. 2011;38:911–9.
Antonsson BE, Avramis VI, Nyce J, Holcenberg JS. Effect of 5-azacytidine and congeners on DNA methylation and expression of deoxycytidine kinase in the human lymphoid cell lines CCRF/CEM/0 and CCRF/CEM/dCk-1. Cancer Res. 1987;47:3672–8.
Candelaria M, de la Cruz-Hernandez E, Taja-Chayeb L, Perez-Cardenas E, Trejo-Becerril C, Gonzalez-Fierro A, Chavez-Blanco A, Soto-Reyes E, Dominguez G, Trujillo JE, et al. DNA methylation-independent reversion of gemcitabine resistance by hydralazine in cervical Cancer cells. PLoS One. 2012;7:e29181.
Mujtaba T, Dou QP. Advances in the understanding of mechanisms and therapeutic use of Bortezomib. Discov Med. 2011;12:471–80.
Camara-Clayette V, Lecluse Y, Schrader C, Klapper W, Vainchenker W, Hermine O, Ribrag V. The NF-κB pathway is rarely spontaneously activated in mantle cell lymphoma (MCL) cell lines and patient’s samples. Eur J Cancer. 2014;50:159–69.
Reece DE, Sullivan D, Lonial S, Mohrbacher AF, Chatta G, Shustik C, Burris H, Venkatakrishnan K, Neuwirth R, Riordan WJ, et al. Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma. Cancer Chemother Pharmacol. 2011;67:57–67.
Weigert O, Pastore A, Rieken M, Lang N, Hiddemann W, Dreyling M. Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma. Leukemia. 2007;21:524–8.
Weigert O, Weidmann E, Mueck R, Bentz M, von Schilling C, Rohrberg R, Jentsch-Ullrich K, Hiddemann W, Dreyling M. A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma – long-term results of a multicenter observation study. Leuk Lymphoma. 2009;50:716–22.
Dreyling M. ClinicalTrials.gov: Bethesda (MD): National Library of Medicine; 2011 Sept 28. Identifier NCT01449344, Efficacy and Safety of R-HAD Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory MCL ((R-HAD)). Cited in 2017 Jun 29. Available from https://clinicaltrials.gov/ct2/show/NCT01449344.
We would like to acknowledge Kristina Lövgren for immunohistochemistry stainings, Ann-Charlott Olsson for gene expression sample and array preparation and Therese Törngren and Professor Åke Borg for TP53 analysis.
The study was supported by Cancerfonden (14–0458) and the Swedish Research Council (K2012-99X-22001-01-3). The funding body had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.
Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
Ethics approval and consent to participate
The study was conducted according to protocols approved by local institutional review board in accordance with the Declaration of Helsinki. The present study was performed using patient material from the Nordic MCL2 and MCL3 trials, all patients have given informed consent to the biobanking and the analysis of molecular markers on tumor tissue, approved by the Ethics committee in Uppsala, Sweden, Dnr 428/2009.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Freiburghaus, C., Emruli, V.K., Johansson, A. et al. Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity. BMC Cancer 18, 466 (2018). https://doi.org/10.1186/s12885-018-4346-1